



## Charles River Associates (CRA) Sponsors Multiple Presentations on Issues in Life Sciences at ISPOR Europe 2018

November 6, 2018

BOSTON--(BUSINESS WIRE)--Nov. 6, 2018-- [Charles River Associates](#) (NASDAQ: CRAI), a worldwide leader in providing [economic, financial, and management consulting services](#), today announced that the Company will present several posters at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 annual meeting taking place November 10-14, 2018 at the International Convention Centre in Barcelona, Spain. Presentations highlight recent and emerging trends in the life sciences industry in areas including the risks and benefits of low pricing strategies, the impact of clinical trial design on market adoption, and access strategies and considerations for curative cell and gene therapies.

"The life sciences specialists at CRA are continually monitoring and analyzing the most recent data and trends affecting the sector as part of our commitment to helping our clients address the issues that affect their operations both regionally and globally," said CRA Vice President, [Joanne Clark](#). "Both the breadth and depth of our presentations at ISPOR Europe this year are a reflection of our ability to offer an insider's perspective on issues related to pricing, access, drug development and commercialization, and many other areas."

Leaders from the CRA Life Sciences Practice will present the following posters in the Exhibit Poster Hall during the ISPOR Europe meeting:

### Monday, November 12, 2018

- Title: Impact of Outcome Based Annuities on Small Biotech Companies  
Authors: Joseph Nevins with Walter Colasante and Luka Jelcic  
Research Poster Presentations: Session I  
PCP: Conceptual Papers  
Display Hours: 8:45 am to 1:45 pm CEST
- Title: The Quantity and Quality of Evidence Supporting European Marketing Authorization of Orphan Drugs: Comparison of Rare Oncology versus Rare Disease  
Author: Steven Kelly  
Research Poster Presentations: Session I  
PSY: Systemic Disorders/Conditions  
Display Hours: 8:45 am to 1:45 pm CEST
- Title: UK Health Technology Assessment of Orphan Drugs for Rare Oncology versus Rare Disease: Does Orphan Designation Make any Difference in HTA Process?  
Author: Steven Kelly  
Research Poster Presentations: Session I  
PSY: Systemic Disorders/Conditions  
Display Hours: 8:45 am to 1:45 pm CEST
- Title: Is Adopting a Low Price Strategy to Gain Market Access Compatible with a Viable Gene/Cell Therapy Business?  
Author: Walter Colasante  
Research Poster Presentations: Session I  
PMU: Multiple Diseases  
Display Hours: 8:45 am to 1:45 pm CEST

### Tuesday, November 13, 2018

- Title: Are Traditional Managed Entry Agreements Suitable for Potentially, Curative Gene/Cell Therapies?  
Author: Walter Colasante  
Research Poster Presentations: Session III  
PHP: Health Care Use & Policy Studies  
Display Hours: 8:45 am to 1:30 pm CEST
- Title: G-BA Conditional Approvals in the AMNOG Procedure: Impact on HTA Outcomes and Price  
Authors: Justus Dehnen with Dennis Petry, Fabian Kruse, and Jakob Bercher  
Research Poster Presentations: Session III  
PHP: Health Care Use & Policy Studies  
Display Hours: 8:45 am to 1:30 pm CEST

- Title: Impact of the Clinical Trial Design Strategy on Product Market Uptake and Overall Commercial Success  
Authors: Leanne Finch with Carla Fisher, Zlatina Dobрева, Jingyi Huang, and Hannah Armstrong  
Research Poster Presentations: Session IV  
PRM: Research on Methods  
Display Hours: 3:30 pm to 7:00 pm CEST

**About CRA's [Life Sciences Practice](#)**

The CRA Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients' toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

**About Charles River Associates (CRA)**

Charles River Associates® is a global consulting firm specializing in [economic, financial, and management consulting services](#). CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at [www.crai.com](http://www.crai.com). Follow us on [LinkedIn](#), [Twitter](#), and [Facebook](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181106005532/en/>

Source: Charles River Associates

Charles River Associates  
Media Relations, 617-425-6453  
[media@crai.com](mailto:media@crai.com)  
or  
Sharon Merrill Associates, Inc.  
Jamie Bernard, 617-542-5300  
Senior Associate